Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The Domingos lab has published a new opinion piece in Science investigating the implications of a Memorial Sloan Kettering Cancer Center study that lays the foundations for a potential new anti-obesity treatment in the form of targeting adipose tissue-resident macrophages.

Adipose tissue-resident macrophages control lipid storage through production of platelet-derived growth
factor (PDGFcc), which induces lipid retention in white adipose tissue adipocytes in a paracrine manner,
although the precise mechanism is unclear. Recruited macrophages are responsible for the inammation
that characterizes obese adipose tissue. Treatment with PDGFcc antibodies restores homeostasis, and
reduces lipid storage and body weight, redirecting excess lipids mostly to thermogenesis. © Science

Immune cells called adipose tissue-resident macrophages control how much fat is stored in the body by secreting a factor that promotes energy storage in adipocytes, also known as fat cells. A new article from Associate Professor Ana Domingos and BHF Cardiovascular Science DPhil Student Conan O’Brien reviews a new study that attempted to prevent promotion of fat storage. In doing so, they present evidence that an anti-obesity immunotherapy has been identified for the first time.

The study, conducted by Dr Nehemiah Cox and Professor Frederic Geissmann at the Memorial Sloan Kettering Cancer Center in New York, showed that an antibody treatment can inhibit the process of storing fat and cause a reduction in body weight, without affecting food intake. The antibody targets a protein called platelet-derived growth factor c, which is secreted by adipose tissue-resident macrophages. The antibodies bind to the protein and inhibit it from promoting fat storage in adipocytes.

According to O’Brien: “This study introduces a new, macrophage-centred paradigm in energy storage and provides proof of concept for an anti-obesity immunotherapy. It is still unclear the extent to which this finding will be translatable to humans, though single cell RNA sequencing of human adipose tissues tells us that human adipose macrophages also express platelet-derived growth factor c, so we could envision the mechanism being conserved and being a clinically relevant target in the future.”

The full article is available to read in Science: "An anti-obesity immunotherapy?"

Similar stories

Key cause of type 2 diabetes uncovered

Research led by Dr Elizabeth Haythorne and Professor Frances Ashcroft reveals high blood glucose reprograms the metabolism of pancreatic beta-cells in diabetes. They have discovered that glucose metabolites, rather than glucose itself, are key to the progression of type 2 diabetes. Glucose metabolites damage pancreatic beta-cell function, so they are unable to release enough of the hormone insulin. Reducing the rate at which glucose is metabolised, and these glucose metabolites build up, can prevent the effects of hyperglycaemia.

New study shows clinical symptoms for Alzheimer’s can be predicted in preclinical models

Establishing preclinical models of Alzheimer’s that reflect in-life clinical symptoms of each individual is a critically important goal, yet so far it has not been fully realised. A new collaborative study from the University of Oxford has demonstrated that clinical vulnerability to an abnormally abundant protein in Alzheimer’s brain is in fact reflected in individual patient induced pluripotent stem cell-derived cortical neurons.

Updating the circuit maps of the sympathetic neural network

A new review from Professor Ana Domingos’ lab and colleagues offers a fresh modern viewpoint on sympathetic neurons and their relation to immune cells and obesity.

New Pfizer grant paves the way to a better understanding of how body fat is controlled

Professor Ana Domingos has been awarded a highly competitive independent research grant from Pfizer to discover ‘the role of Sympathetic-associated Perineurial barrier Cells in obesity’.

Collaborative MRC grant paves the way to new therapeutic targets for stress and anxiety disorders

Dr Armin Lak, Associate Professor Ed Mann and Professor Zoltán Molnár have been awarded a £733K Project Grant from the Medical Research Council on “Orexinergic projections to neocortex: potential role in arousal, stress and anxiety-related disorders”.